Disc Medicine (IRON) Income from Continuing Operations (2020 - 2026)
Disc Medicine (IRON) reported Income from Continuing Operations of 63453000.0 for Q1 2026, down 86.81% year-over-year from 481188791.69 in Q1 2025, and down 4.26% quarter-over-quarter from 60860000.0 in Q4 2025.
Disc Medicine (IRON) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has 7 years of Income from Continuing Operations data on file, last reported at 63453000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 63453000.0, down 86.81% year-over-year; the trailing twelve-month figure through Mar 2026 was 241881000.0 (down 107.96% YoY), and the FY2025 annual result was 212513000.0, down 94.33% from the prior year.
- Income from Continuing Operations slipped to 63453000.0 in Q1 2026 per IRON's latest filing, from 60860000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 9580000.0 in Q2 2022 and troughed at 63453000.0 in Q1 2026.
- A 5-year average of 29902470.59 and a median of 26287000.0 in 2024 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 46.27% in 2022 and fell as far as 161.83% in 2022.
- A 5-year view of Income from Continuing Operations shows it stood at 11244000.0 in 2022, then sank by 109.41% to 23546000.0 in 2023, then declined by 25.1% to 29457000.0 in 2024, then slumped by 106.61% to 60860000.0 in 2025, then fell by 4.26% to 63453000.0 in 2026.
- Business Quant data shows IRON's Income from Continuing Operations at 63453000.0 in Q1 2026, 60860000.0 in Q4 2025, and 62321000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Disc Medicine | 2.73 Bn | 2.00 Bn | - | -63.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.45 Mn |
| Dec 31, 2025 | -60.86 Mn |
| Sep 30, 2025 | -62.32 Mn |
| Jun 30, 2025 | -55.25 Mn |
| Mar 31, 2025 | -33.97 Mn |
| Dec 31, 2024 | -29.46 Mn |
| Sep 30, 2024 | -26.60 Mn |
| Jun 30, 2024 | -26.29 Mn |
| Mar 31, 2024 | -26.95 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -14.10 Mn |
| Jun 30, 2023 | -15.95 Mn |
| Mar 31, 2023 | -22.78 Mn |
| Dec 31, 2022 | -11.24 Mn |
| Sep 30, 2022 | -16.15 Mn |
| Jun 30, 2022 | -9.58 Mn |
| Mar 31, 2022 | -9.85 Mn |
| Dec 31, 2021 | 18.19 Mn |
| Sep 30, 2021 | -18.45 Mn |
| Jun 30, 2021 | -16.44 Mn |